

Clinical trials: Reading between the lines

Dr Andrew Hitchings

Senior lecturer in clinical pharmacology / Consultant in neuro-intensive care

A seminal study (1980)



- 1073 patients with angiographically-proven CAD
- Randomised to two management strategies
- Planned analyses:
 - Primary endpoint: all-cause mortality
 - Multivariable survival analysis over 5 years of follow-up
 - Biologically-relevant subgroup analyses

Baseline characteristics



 Generally well-balanced
Slightly higher prevalence of LV impairment in Group 2

	Prevalence (%)		
	$\begin{array}{c} \text{Total} \\ (n = 1073) \end{array}$	Group 1 (n = 539)	$\begin{array}{l} \text{Group 2} \\ (n = 534) \end{array}$
Males	85	84	85
Age > 50 years	53	53	53
History of previous MI	51	49	53
History of CHF	14	14	14
Cardiomegaly on chest x-ray	20	18	22
Diagnostic Q waves on ECG	43	41	46
Resting ST-T-wave abnormalities	47	47	47
LVEDP > 18 mm Hg	15	14	15
$AVO_2D > 5.5$ vol %	19	19	18
Single-vessel disease	24	24	24
Three-vessel disease	51	51	51
Abnormal LV contraction	60	57	63
Significant mitral insufficiency	8	6	10
Left main stenosis $\geq 50\%$	16	17	15

Abbreviations: MI = myocardial infarction; CHF = congestive heart failure; LVEDP = left ventricular end-diastolicpressure; AVO₂D = arteriovenous oxygen difference; LV =left ventricular.





Overall survival similar

Subgroup analyses




Number of significantly diseased vessels
Presence or absence of LV impairment
Symptoms of congestive cardiac failure



Subgroup analyses

 Triple-vessel disease and LV impairment (n=397)



Subgroup analyses



...And no established symptoms of CCF (n=298)

- 3-year survival: 60% vs. 80% (P<0.01)
- Independent of other variables (P<0.01)
- Still significant after correction for multiple comparisons

Study conclusion



- Treatment approach made no difference to survival in the population as a whole
- But there was a clinically and statistically significant difference in a sizable minority:
 - 20% absolute difference at 3 years (NNT 5)

Interpretation

- What treatment was studied in this trial?
- What do you think about the analysis and findings?

There was no treatment...

508

CIRCULATION

Vol 61, No 3, March 1980

Lessons from a Simulated Randomized Trial in Coronary Artery Disease

KERRY L. LEE, PH.D., J. FREDERICK MCNEER, M.D., C. FRANK STARMER, PH.D.,

PHILIP J. HARRIS, M.B., D.PHIL., AND ROBERT A. ROSATI, M.D.


SUMMARY A simulated randomized clinical trial in coronary artery disease was conducted to illustrate the need for clinical judgment and modern statistical methods in assessing therapeutic claims in studies of complex diseases. Clinicians should be aware of problems that occur when a patient sample is subdivided and treatment effects are assessed within multiple prognostic categories. In this example, 1073 consecutive, medically treated coronary artery disease patients from the Duke University data bank were randomized into two groups. The groups were reasonably comparable and, as expected, there was no overall difference in survival. In a subgroup of 397 patients characterized by three-vessel disease and an abnormal left ventricular contraction, however, survival of group 1 patients was significantly different from that of group 2 patients. Multivariable adjustment procedures revealed that the difference resulted from the combined effect of small imbalances in the distribution of several prognostic factors. Another subgroup was identified in which a significant survival difference was not explained by multivariable methods.


These are not unlikely examples in trials of a complex disease. Clinicians must exercise careful judgment in attributing such results to an efficacious therapy, as they may be due to chance or to inadequate baseline comparability of the groups.



Clinical trials: Reading between the lines

Multiplicity





Multiplicity is everywhere, both open and hidden

- Multiple questions, subgroups and endpoints
- Multiple methods of analysis
- Multiple trials, published and unpublished
- Multiplicity 'threatens the validity of every statistical conclusion'¹




RESEARCH ARTICLE

PSYCHOLOGY

Estimating the reproducibility of psychological science

Open Science Collaboration*†



Science 2015;349:aac4716

Clinical trials: Reading between the lines

1. Multiplicity


Clinical trials: Reading between the lines

- 1. Multiplicity
- 2. Heterogeneity

The tacit homogeneity assumption


- Therapeutic effects are evenly distributed among trial participants
- Spread of treatment effects in the trial reflects the spread in the population from which it was drawn

Selection biases




Statist Med 1999;18:1467-74

Simple random sampling




Centre-biased sample



ST GEORGE'S / CLINICAL PHARMACOLOGY


Statist Med 1999;18:1467-74

Tail-biased sample





Statist Med 1999;18:1467-74

Benefit from treatment depends on baseline risk
Harm from treatment is distributed fairly randomly




Baseline risk





Treatment of carotid stenosis




N Engl J Med 1991;325:445-53

Implications of heterogeneity

 Heterogeneity of treatment effect within the trial sample

Look for the test for interaction



ST GEORGE'S / **CLINICAL** PHARMACOLOGY

N Engl J Med 2016;374:2313-23


Implications of heterogeneity

- Heterogeneity of treatment effect within the trial sample
- Estimates of population parameters
 - Biased estimate of mean treatment effect
 - Underrepresentation of population hetereogeneity

Clinical trials: Reading between the lines


- 1. Multiplicity
- 2. Heterogeneity

A new agent to treat migraine



N Engl J Med 2017;377:2123-32

A new agent to treat migraine



N Engl J Med 2017;377:2123-32

Clinical trials: Reading between the lines

- 1. Multiplicity
- 2. Heterogeneity
- 3. 'Placebo' effects


Phenomena contributing to 'placebo' effects

- Hawthorne effects
- Expectation effects
 - Placebo effects
 - Nocebo effects

Phenomena contributing to 'placebo' effects


- Hawthorne effects
- Expectation effects
 - Placebo effects
 - Nocebo effects

Changing behaviour of the placebo group




Pain 2015;156:2616-26

Nocebo effects in multiple sclerosis




Trials of symptomatic therapy



Why even bother with drugs...?

ORIGINAL ARTICLE

Tiotropium in Asthma Poorly Controlled with Standard Combination Therapy




ST GEORGE'S / CLINICAL PHARMACOLOGY

N Engl J Med 2012;367:1198-207

Why even bother with drugs...?

ORIGINAL ARTICLE

Placebo in Asthma Poorly Controlled with Standard Combination Therapy




N Engl J Med 2012;367:1198-207


PATIENT CHARACTERISTICS

Eligible patients were between the ages of 18 and 75 years and had a 5-year or longer histor 40 years. Patients were required to have a to 6 (maximum impairment), with a minimal clinically important difference of 0.5 units8; and to have persistent airflow limitation, which was defined as a post-bronchodilator forced expiratory volume in 1 second (FEV₁) of 80% or less of of albuterol at the screening visit, despite budesonide or the equivalent) and LABAs. Pa tion that was treated with systemic glucocorticoids in the previous year and to be either lifelong nonsmokers or to have a smoking history of fewer than 10 pack-years, with no smoking in the vear before enrollment.

of asthma that was diagnosed before the 40 years. Patients were required to have a score 40 years. Patients were required to have a of 1.5 or higher on the Asthma Control Que of 1.5 or higher on the Asthma Control Que naire 7 (ACQ-7), which consists of seven que each scored on a range from 0 (no impair naire 7 (ACQ-7), which consists of seven que naire 7 (ACQ-7), which consists of seven que


the predicted value⁹ and 70% or less of defined as a post-bronchodilator forced expiraof four puffs of 100 µg of salbutamol or of albuterol at the screening visit, despite therapy with inhaled glucocorticoids (≥800 budesonide or the equivalent) and LABAS. Pa were required to have had at least one exa vital capacity (FVC) 30 minutes after the inhalation







Score range

ST GEORGE'S / CLINICAL PHARMACOLOGY





Score range



Score range

Phenomena contributing to 'placebo' effects

- Hawthorne effects
- Expectation effects
 - Placebo effects
 - Nocebo effects
- Regression to the mean

- A purely statistical phenomenon
- Occurs whenever a population is:
 - Asymmetrically sampled
 - Measured more than once
 - Correlation between the measurements is imperfect
- Best handled by comparing to a placebo group

Summary

- The problems of multiplicity are serious and allpervasive
- Understand the implications of heterogeneity of treatment effect
- Understand the factors that contribute to 'placebo' effects